Wang Lili, Xian Hong, Guo Jiajun, Li Weihao, Wang Jiaqi, Chen Qing, Fu Xiaoyu, Li Hongbao, Chen Qin, Zhang Wei, Chen Yucheng
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.
Front Cardiovasc Med. 2022 Oct 11;9:923655. doi: 10.3389/fcvm.2022.923655. eCollection 2022.
Given the rapid innovation of wearable technology, additional physical indicators can be detected, and blood pressure (BP) has become the focus of many emerging medical-device manufacturers. This study aimed to validate the accuracy of the newly developed HUAWEI WATCH in BP monitoring, according to the American National Standards Institute/Association for the Advancement of Medical Instrumentation/International Organization for Standardization (ANSI/AAMI/ISO 81060-2:2018) guidelines.
The same arm sequential BP measurement was applied. One validation included four reference BP measurements taken simultaneously by two independent observers using a mercury sphygmomanometer, alternating with three test-watch measurements. Each test-watch measurement was compared against the average of the previous and subsequent reference BP readings. Two criteria were required for validation: (1) a mean BP difference of 5 mm Hg or less, with a standard deviation (SD) of 8 mm Hg or less for systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the 255 pairs of measurements, and (2) an SD for the of 85 averaged BP differences within the threshold defined by the mean test-reference BP difference listed in the ANSI/AAMI/ISO 81060-2:2018 guidelines.
The mean age of the 85 participants was 48 ± 18 years (range: 21-85), and 53 (62.4%) were male. The mean differences between the test and reference BPs were -0.25 ± 5.62 mm Hg and -1.33 ± 6.81 mm Hg for SBP and DBP, respectively (according to Criterion 1). The mean differences between the test BPs and reference BPs were -0.25 ± 5.00 mm Hg and -1.33 ± 6.31 mm Hg for SBP and DBP, respectively, according to Criterion 2.
Blood pressure measurement using the HUAWEI WATCH showed excellent consistency with reference BPs, and fulfilled both validation criteria of the guidelines, show its promise as a wearable device for BP self-monitoring.
鉴于可穿戴技术的迅速创新,可检测到更多的身体指标,血压(BP)已成为许多新兴医疗设备制造商关注的焦点。本研究旨在根据美国国家标准学会/医疗仪器促进协会/国际标准化组织(ANSI/AAMI/ISO 81060-2:2018)指南,验证新开发的华为手表在血压监测方面的准确性。
采用同一手臂连续测量血压。一项验证包括由两名独立观察者使用水银血压计同时进行的四次参考血压测量,与三次手表测试测量交替进行。每次手表测试测量结果与前一次和后一次参考血压读数的平均值进行比较。验证需要满足两个标准:(1)在255对测量中,收缩压(SBP)和舒张压(DBP)的平均血压差值为5毫米汞柱或更小,标准差(SD)为8毫米汞柱或更小;(2)在ANSI/AAMI/ISO 81060-2:2018指南列出的平均测试-参考血压差值定义的阈值内,85个平均血压差值的标准差。
85名参与者的平均年龄为48±18岁(范围:21-85岁),其中53名(62.4%)为男性。根据标准1,测试血压与参考血压之间的平均差值,SBP为-0.25±5.62毫米汞柱,DBP为-1.33±6.81毫米汞柱。根据标准2,测试血压与参考血压之间的平均差值,SBP为-0.25±5.00毫米汞柱,DBP为-1.33±6.31毫米汞柱。
使用华为手表测量血压与参考血压显示出极佳的一致性,并满足了指南的两项验证标准,表明其有望成为一种用于血压自我监测的可穿戴设备。